GSK PLC starts three-year plan after £1.33B cough hit
GSK plc said Tuesday it is rolling out a three-year restructuring program designed to cut costs and free cash for late-stage research, while taking a £1.33 billion hit after scrapping chronic cough candidate camlipixant. The Accelerate Growth plan aims to save £1.9 billion a year by 2029.
The UK drugmaker detailed the move in its second-quarter earnings release, framing the overhaul as a way to simplify its business and product portfolio. Cash and other resources are meant to shift toward the late-stage pipeline and R&D. For more market-moving headlines, see our Celebrity Breaking News hub.
Key Takeaways
- GSK plc launched Accelerate Growth, targeting £1.9 billion ($2.5 billion) in annual savings by 2029.
- Implementing the three-year restructuring is expected to cost about £2.4 billion, mostly this year and next.
- A £1.33 billion impairment followed the decision to end camlipixant development after a Phase 3 chronic cough failure.
- GSK bought Bellus Health, the drug’s original developer, for $2 billion in 2023.
- Partner Hansoh Pharma reported positive Phase 3 osteosarcoma data for Ris-Rez, which GSK is also testing.
What did GSK plc announce in its Q2 update?
According to Endpoints News, GSK plc said it is starting a three-year restructuring program called Accelerate Growth. The company said the plan should save £1.9 billion a year by 2029.
Management said the changes are designed to streamline focus on key advanced assets. The company also tied the effort to its longer-term ambition of more than £40 billion in sales by 2031.
Putting the plan in place is expected to cost GSK £2.4 billion. Much of that spend is set to land this year and next, so near-term charges will accompany the promised later savings.
Why did GSK take a £1.33 billion impairment?
In the same quarter, GSK booked a £1.33 billion impairment charge after ending development of camlipixant in chronic cough. The decision followed an earlier report that the drug failed a Phase 3 study.
Camlipixant came from Bellus Health, which GSK acquired for $2 billion in 2023. The write-down underlines how clinical setbacks can quickly erase acquisition value and pressure earnings even when a broader cost plan is underway.
Ahead of the report, Seeking Alpha noted consensus expectations for a sharp year-over-year EPS contraction, putting investor focus on guidance and how leadership explains both the trial hit and the savings roadmap.
How does the savings plan fit GSK’s pipeline bets?
GSK said Accelerate Growth should free resources for late-stage assets and R&D rather than simply shrinking the company. That message matters because the cough failure adds to what Endpoints described as growing costs tied to clinical setbacks.
There was also a brighter pipeline note: partner Hansoh Pharma reported positive Phase 3 osteosarcoma results in China for Ris-Rez, a B7-H3-targeted antibody-drug conjugate. Hansoh said the treatment showed statistically significant and clinically meaningful improvements in progression-free survival versus chemotherapy.
GSK is testing Ris-Rez in a separate global Phase 1b/2 trial enrolling patients with previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma. The contrast is clear: cut costs and write off a failed cough bet, while still pushing oncology assets that could support the 2031 sales goal.